Cargando…

PB1959: ESTABLISHMENT OF A NEW MULTIPLE MYELOMA (MM) RESEARCH MODEL USING MAGNETICALLY EMPOWERED TUMOR CELLS AND NK CELLS

Detalles Bibliográficos
Autores principales:	Wang, Z., Hou, R., Tan, L., Zhang, J., Zhang, D., Pan, D., Chen, Q., Tang, L., Hu, Y., Kong, X., Jiang, Q.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429096/ http://dx.doi.org/10.1097/01.HS9.0000850672.64749.00

Ejemplares similares

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
por: Gkioka, Annita-Ioanna, et al.
Publicado: (2023)

PB2075: HOW EFFECTIVE ARE LEPTIN GENE POLYMORPHISMS AND METHYLATION DURING THE COURSE OF MULTIPLE MYELOMA (MM)?
por: Serin, Istemi, et al.
Publicado: (2023)

PB2033: INFLUENCE OF INDUCTION THERAPY WITH LENALIDOMIDE ON MAINTENANCE THERAPY AND PROGNOSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Sun, Q., et al.
Publicado: (2022)

PB2005: BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY OF CHINA
por: Jingyu, X., et al.
Publicado: (2022)

PB2086: CHRONIC LYMPHOPROLIFERATIVE DISORDER OF NK CELLS WITH LIVER INFILTRATION
por: Otasevic, V., et al.
Publicado: (2022)

PB1765: EFFICACY OF A NEW INDUCTION REGIMEN IN THE TREATMENT OF EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Wang, M., et al.
Publicado: (2022)

PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
por: Gaspo, Rania, et al.
Publicado: (2023)

PB2278: INVESTIGATION ON THE STATUS OF INFECTION IN PATIENTS WITH MULTIPLE MYELOMA
por: Lan, D., et al.
Publicado: (2022)

PB2125: VCD VERSUS VRD‐BASED REGIMENS AS INDUCTION THERAPIES IN PATIENTS WITH PRIMARY MULTIPLE MYELOMA (MM): HIGHLIGHTING STRATEGIES THAT ACTUALLY WORK.
por: Novosad, Olga, et al.
Publicado: (2023)

PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)
por: Holstein, Sarah A., et al.
Publicado: (2023)

PB2362: BEST PRACTICES ON EMPOWERING AND INVOLVING PATIENTS LIVING WITH HEMATOLOGICAL MALIGNANCIES ON THE DEVELOPMENT OF NOVEL PATIENT-REPORTED OUTCOME MEASURES
por: Vrontaras, N., et al.
Publicado: (2022)

PB1715: UNLEASHING NATURAL KILLER (NK) CELLS TO PROMOTE ANTI-LEUKEMIC IMMUNITY
por: Tsoukala, Ioanna, et al.
Publicado: (2023)

PB2148: EFFICACY OF SMALL MOLECULE TARGET THERAPIES IN REFRACTORY OR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA AND MOLECULAR SUBTYPING: A MULTI-CENTER REAL-WORLD EVIDENCE
por: Zhang, Y., et al.
Publicado: (2022)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT
por: Zhao, Jie, et al.
Publicado: (2023)

PB1952: EFFECTS OF KNOCKDOWN OF NUPR1 GENE ON THE PROLIFERATION AND APOPTOSIS OF MULTIPLE MYELOMA CELLS AND ITS MECHANISM
por: Zeng, C., et al.
Publicado: (2022)

PB1970: AS2O3 INDUCE IMMUNOGENIC CELL DEATH IN MULTIPLE MYELOMA VIA NLRP3/CASPASE SIGNALING PATHWAY
por: Si, Y., et al.
Publicado: (2022)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

PB1974: MULTIVARIATE SPECTRAL BIOTYPING OF EXTRAMEDULLARY MULTIPLE MYELOMA
por: Vlachová, M., et al.
Publicado: (2022)

PB2277: ANALYSIS ON POLLUTION STATUS AND INFLUENCING FACTORS OF NURSES’ UNIFORMS IN HEMATOLOGY GENERAL WARD
por: Du, X., et al.
Publicado: (2022)

PB2011: CHIDAMIDE COMBINED WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (TC2D) AS AN ORAL QUADRUPLET REGIMEN FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: INITIAL RESULTS OF A PHASE IIA, MULTICENTER TRIAL
por: Li, Y., et al.
Publicado: (2022)

PB2336: TREATMENT PATTERN AND OUTCOME IN SYSTEMIC T AND NK CELL LYMPHOMA: AN ASIAN SINGLE CENTER EXPERIENCE
por: Sung, Meng-Ta, et al.
Publicado: (2023)

PB2370: EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMA, NASAL-TYPE: ABOUT 11 CASES
por: Aghoutane, Yossra, et al.
Publicado: (2023)

PB1972: PAEONIFLORIN ALLEVIATES BIPN BY REDUCING IL6 LEVELS AND MODULATING PARKIN-MEDIATED MITOPHAGY
por: Sun, R., et al.
Publicado: (2022)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

PB1990: MULTIPLE MYELOMA IN THE ELDERLY: A MONOCENTRIC EXPERIENCE
por: Charfi, H., et al.
Publicado: (2022)

PB1961: ZNO NANOPARTICLES INDUCE MULTIPLE MYELOMA CELL DEATH BASED ON REACTIVE OXYGEN SPECIES AND CASPASE SIGNALING PATHWAY
por: Li, Z., et al.
Publicado: (2022)

PB1955: THE AGENDA FOR FUTURE MULTIPLE MYELOMA RESEARCH ACCORDING TO PATIENTS, CAREGIVERS, AND CLINICIANS
por: Fowler, S., et al.
Publicado: (2022)

PB1976: CRISPR-CAS9 KNOCKOUT SCREEN IDENTIFIES RNA MODIFICATION ENZYMES ESSENTIAL FOR CELL SURVIVAL IN MULTIPLE MYELOMA
por: Zhao, D., et al.
Publicado: (2022)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

PB2100: REAL-WORLD TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A RETROSPECTIVE CHART STUDY
por: Guillaume, Xavier, et al.
Publicado: (2023)

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM-6
por: Girnius, Saulius K., et al.
Publicado: (2023)

PB1977: SPECTRUM OF INFECTIOUS COMPLICATIONS FOLLOWING TRANSPLANTATION OF AUTOLOGOUS BLOOD STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA
por: Abakumova, A., et al.
Publicado: (2022)

PB2083: IN-VITRO EVALUATION OF LENALIDOMIDE ENANTIOMERS AGAINST HUMAN MULTIPLE MYELOMA CELL LINE
por: Vardhan, Gyan, et al.
Publicado: (2023)

PB2104: SOLUBLE B-CELL MATURATION ANTIGEN AS A MONITORING MARKER FOR MULTIPLE MYELOMA
por: Wiedemann, Ádám, et al.
Publicado: (2023)

PB2269: HUMORAL AND T-CELL RESPONSES TO SARS-COV2 VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA MANAGED IN THE COMMUNITY SETTING
por: Holik, H., et al.
Publicado: (2022)

PB2108: PREVALENCE AND CLINICAL IMPLICATIONS OF CYCLIN D1 POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA IN CHINA
por: Liang, X., et al.
Publicado: (2022)

PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Weisel, Katja, et al.
Publicado: (2023)

PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY
por: Bernardi, Simona, et al.
Publicado: (2023)

PB1975: THE RESEARCH ON THE MECHANISM OF RRAD GENE IN MULTIPLE MYELOMA
por: Yi, C., et al.
Publicado: (2022)

PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA
por: Bougherira, S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2arcpte4c7r0ihe1bbqj71aka6